Scientists unveiled a high-throughput strategy to target MDM2 in an effort to overcome radiation resistance in uveal melanoma. The work frames radiation therapy resistance as a key barrier for ocular oncology outcomes and positions MDM2 modulation as a way to restore sensitivity. By using high-throughput methods, the strategy aims to accelerate identification of effective combinations or dosing schedules that can be tested more efficiently across radiation-resistant contexts.